Obesity pill may treat diabetes

	Tweet

A new obesity pill that helps control blood sugar levels in patients with type 2 diabetes could provide a novel way to treat the illness, a team of international researchers said on Friday.

They found that rimonabant, sold by Sanofi-Aventis under the trade name Acomplia, reduced risk factors for heart disease in patients with type 2 diabetes who did not respond to standard treatments.

“These findings support the use of 20 milligrams (mg) per day of rimonabant, in addition to diet and exercise, as a new approach to reduce body weight and improve blood glucose control as well as other cardiovascular risk factors in overweight or obese patients with type 2 diabetes,” said Professor Andre Scheen of the University of Liege in Belgium.

Diabetes affects about 194 million people worldwide. Most cases are type 2 diabetes, caused by an inability to regulate glucose (sugar) in the body properly, which are linked to being overweight or obese.

Reducing weight and controlling glucose levels is important because diabetics have an increased risk of heart disease, stroke, blindness, kidney damage and nerve disorders, which can lead to foot ulceration and amputations.

“Type 2 diabetes is a difficult disease to treat because we have had no optimal drugs until now,” Scheen told Reuters. “Available drugs can improve blood glucose control but unfortunately they promote weight gain, instead of weight loss.”

In a study of 1,047 overweight and obese diabetes patients in 11 countries in Europe and North and South America, the researchers compared the impact of taking either 5 mg or 20 mg of the drug a day to a placebo for a year.

Compared with patients taking a placebo, those on rimonabant lost more weight and had greater decreases in waist circumference and abdominal fat. Improvements in appetite and blood glucose control were also greater in the treatment group.

Scheen said the findings, published online by The Lancet medical journal, confirm results from earlier studies of the drug in overweight or obese patients without diabetes.

The drug was generally well tolerated, although some patients developed nausea, vomiting and anxiety.

“This drug is able to target several cardiovascular and metabolic risk factors,” said Scheen.

RELATED STORIES:
Phone contact with nurses linked with better outcomes for women with gestational diabetes   Death rate drops among Americans with diabetes -CDC   Correct treatment of common diabetic foot infections can reduce amputations   “Pre-diabetes,” diabetes rising among U.S. teens   Experimental bariatric surgery controls blood sugar in rats with diabetes   53 millions Americans might develop diabetes by 2025   New inflammation hormone link may pave way to study new drugs for type 2 diabetes   Diabetic retinopathy research could reduce screening costs   Liver fat gets a wake-up call that maintains blood sugar levels   Low testosterone levels could raise diabetes risk for men   Prosthetic lets diabetic get a foot up on life   Dealing with Diabetes, One Patient at a Time

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]